A Phase 4 interventional study of sildenafil citrate and sildenafil citrate in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 82 sites in 23 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-05-13.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one has the largest enrollment, is the only one that started in 2014, is one of 6 in phase 4, and was the 16th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 385 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2014, is one of 4 in phase 4, and was the 13th registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]). In addition, the relative effects on clinical worsening and 6-minute walking distance (6MWD) will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects ≥ 18 \<75 years of age with any of the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: sildenafil citrate
Drug: sildenafil citrate
Drug: sildenafil citrate
sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
Also known as: Revatio
sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
Also known as: Revatio
sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
Also known as: Revatio
Overall Survival
In this outcome measure number of deaths during the study were reported.
Time frame: Day 1 of study treatment up to date of death (within a maximum duration of 2102 days)
Number of Participants With Clinical Worsening Events
Clinical worsening was defined as all-cause mortality, non-elective hospital stay for worsening pulmonary arterial hypertension (PAH) (including but not limited to right heart failure \[RHF\], initiation of intravenous (IV) prostanoids, lung transplantation, or septostomy) or disease progression. Disease progression was defined as a reduction from baseline in the 6-Minute Walk Distance (6MWD) test by 15% and worsening functional class from baseline, both confirmed by second test within 2 weeks of study treatment.
Time frame: Day 1 of study treatment up to date of clinical worsening event (within a maximum duration of 2080 days)
Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 6
6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.
Time frame: Baseline, Month 6
Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 12
6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.
Time frame: Baseline, Month 12
This was a randomized, double-blind, parallel-group, multinational and multicenter study to assess the effects of oral sildenafil on mortality in adult participants with pulmonary arterial hypertension (PAH). The study was conducted at 68 active sites in 23 countries.
| Milestone | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| Started | 129 | 128 | 128 |
| Completed | 0 | 0 | 0 |
| Not completed | 129 | 128 | 128 |
| Withdrew: Other | 1 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 10 | 4 |
| Withdrew: Study terminated by sponsor | 87 | 89 | 100 |
| Withdrew: Randomized in error | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 | 2 |
| Withdrew: Death | 34 | 25 | 19 |
| Withdrew: Adverse event | 0 | 0 | 1 |
In this outcome measure number of deaths during the study were reported.
| Participants | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| Overall Survival | 34 | 25 | 19 |
Clinical worsening was defined as all-cause mortality, non-elective hospital stay for worsening pulmonary arterial hypertension (PAH) (including but not limited to right heart failure \[RHF\], initiation of intravenous (IV) prostanoids, lung transplantation, or septostomy) or disease progression. Disease progression was defined as a reduction from baseline in the 6-Minute Walk Distance (6MWD) test by 15% and worsening functional class from baseline, both confirmed by second test within 2 weeks of study treatment.
| Participants | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| Number of Participants With Clinical Worsening Events | 52 | 36 | 28 |
6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.
| Meters | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 6 | 12.2 (-0.67 to 25.16) | 27.3 (14.52 to 39.99) | 31.2 (18.68 to 43.66) |
6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Analysis was performed using mixed model for repeated measures (MMRM), adjusted for baseline 6MWD and for randomization stratification factors: PAH treatment at study entry and etiology of PAH.
| Meters | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| Change From Baseline in 6-Minute Walk Distance (6MWD) at Month 12 | 14.3 (-0.58 to 29.27) | 35.7 (20.91 to 50.48) | 34.8 (20.21 to 49.43) |
Collected over Baseline up to 28 days after last dose of study treatment (up to a maximum duration of 2108 days for sildenafil 5 mg; up to a maximum duration of 2012 days for sildenafil 20 mg; up to a maximum duration of 2101 days for sildenafil 80 mg). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil 5 mg | 34/129 (26.4%) | 66/129 (51.2%) | 108/129 (83.7%) |
| Sildenafil 20 mg | 25/128 (19.5%) | 49/128 (38.3%) | 107/128 (83.6%) |
| Sildenafil 80 mg | 19/128 (14.8%) | 51/128 (39.8%) | 111/128 (86.7%) |
| Event | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 17/129 | 10/128 | 8/128 |
| Right ventricular failureCardiac disorders | 11/129 | 4/128 | 2/128 |
| Cardiac failureCardiac disorders | 9/129 | 8/128 | 3/128 |
| PneumoniaInfections and infestations | 7/129 | 6/128 | 3/128 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/129 | 1/128 | 4/128 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 2/129 | 4/128 | 2/128 |
| Acute kidney injuryRenal and urinary disorders | 4/129 | 1/128 | 2/128 |
| Cardiac arrestCardiac disorders | 1/129 | 3/128 | 0/128 |
| Cardiac failure congestiveCardiac disorders | 3/129 | 2/128 | 3/128 |
| AppendicitisInfections and infestations | 0/129 | 1/128 | 3/128 |
| Event | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 26/129 | 45/128 | 33/128 |
| DiarrhoeaGastrointestinal disorders | 13/129 | 17/128 | 20/128 |
| NasopharyngitisInfections and infestations | 19/129 | 16/128 | 19/128 |
| DizzinessNervous system disorders | 12/129 | 15/128 | 18/128 |
| Oedema peripheralGeneral disorders | 14/129 | 17/128 | 8/128 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/129 | 16/128 | 11/128 |
| NauseaGastrointestinal disorders | 16/129 | 12/128 | 8/128 |
| Upper respiratory tract infectionInfections and infestations | 16/129 | 8/128 | 13/128 |
| Back painMusculoskeletal and connective tissue disorders | 16/129 | 10/128 | 14/128 |
| Chest painGeneral disorders | 7/129 | 15/128 | 13/128 |
All randomized participants were included in the baseline analysis population.
| Age, Continuous(Years) | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg | Total |
|---|---|---|---|---|
| Mean | 51.4 ± 15.02 | 51.2 ± 15.81 | 52.1 ± 14.72 | 51.6 ± 15.16 |
| Sex: Female, Male(Participants) | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg | Total |
|---|---|---|---|---|
| Female | 97 | 102 | 98 | 297 |
| Male | 32 | 26 | 30 | 88 |
| Ethnicity (NIH/OMB)(Participants) | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 3 | 12 |
| Not Hispanic or Latino | 124 | 124 | 125 | 373 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sildenafil 5 mg | Sildenafil 20 mg | Sildenafil 80 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 23 | 14 | 19 | 56 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 104 | 113 | 108 | 325 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2014 to primary completion in Feb 2021, 77 months.
Results were first posted in May 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →